General News

Hungary compares five anticovid vaccines and highlights the high efficacy of Sputnik V

Posted: 26 Nov 2021 05:29 GMT

The effectiveness of the Russian vaccine in preventing deaths from COVID-19 was between 95.4% and 100%, while all vaccines were shown to be 100% effective among individuals who were 16 to 44 years old.

Hungary has studied the efficacy of five coronavirus vaccines used in the national territory in a total of 3,740,066 people who received the full product guideline from Pfizer / BioNTech (1,497,011 vaccinated), Sinopharm (895,465 vaccinated), Sputnik V (820,560 vaccinated), AstraZeneca (304,138 vaccinated) or Modern (222,892 vaccinated), and has highlighted a “high or very high efficacy” of all of them both for the prevention of covid-19 and for the prevention of deaths due to the disease.

Regarding the prevention of deaths, the Russian Sputnik V vaccine achieved results of between 95.4% and 100% in different age groups, “demonstrating a very high and persistent efficacy both among older and younger people”. For the AstraZeneca vaccine, efficacy varied between 74.5% and 100%, while for Moderna, Pfizer and Sinopharm vaccines it was estimated at 93.6%, 90.6% and between 67.5% and 100%, respectively, about seven days after the injection of the second dose of each drug.

Protection against infection was lower for all the vaccines studied, but it is still considered very good. Thus, Sputnik V demonstrated an efficacy of the 85.7% seven days after the second dose. AstraZeneca achieved an average protection of 68.27% – 77.22% against contagion after the two doses among those under 65 years of age, who constituted 73.9% of those inoculated with this drug who were part of the study.

They estimate that Pfizer and Moderna vaccines cause 30 times more cases of portal vein thrombosis than AstraZeneca's

Pfizer’s vaccine was shown to be effective when 83.3% one week after injection of the second component and to 84% within two weeks. For Moderna, efficacy against infection was the 88.7%, while for Sinopharm it was 68.7%.

Hungary was the first country in the European Union to authorize Sputnik V. The data analyzed in the study belongs to the National Center for Public Health and covers the period between January 22 and June 10 of this year.

Following the publication of the results of the comparative analysis, Kiril Dmitriev, executive director of the Russian Direct Investment Fund (RDIF), stated that “Sputnik V has shown the best results among five vaccines” administered in Hungary.

About the author

Donna Miller

Donna is one of the oldest contributors of Gruntstuff and she has a unique perspective with regards to Science which makes her write news from the Science field. She aims to empower the readers with the delivery of apt factual analysis of various news pieces from Science. Donna has 3.5 years of experience in news-based content creation, and she is now an expert at it. She loves journalism, and that is the reason, she moved from a web content writer to a News writer, and she is loving it. She is a fun-loving woman who has very good connections with every team member. She makes the working environment cheerful which improves the team’s work productivity.

Add Comment

Click here to post a comment